Navigation Links
Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:10/30/2008

LONDON and NEW YORK, Oct. 30 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, Nov. 10 from 10:45 to 11:10 a.m. in the Louis room (4th Floor) at The New York Palace Hotel.

Dr. Cohen's presentation will provide an overview of Morria's development of its leading clinical programs in allergic rhinitis (hay fever) and skin inflammation (contact dermatitis), as well as its pre-clinical progress in asthma, inflammatory bowel disease, ophthalmology and cystic fibrosis. The presentation will include a review of the clinical results reported from Morria's recently completed Phase II double blind placebo controlled study in 105 patients suffering from allergic rhinitis, a study that also included a steroid comparator.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of novel, anti-inflammatory pharmaceuticals termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including respiratory, skin, airway and gastro-intestinal inflammatory diseases. For more information please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer - Investors

cheer@rlcinc.com

Tim Rathschmidt - Media

trathschmidt@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
3. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
4. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
5. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
6. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
10. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... The Pittcon ... Pittcon 2019. Chuck has been a volunteer member of Committee since 1987. Since ... the board of directors and treasurer and was chairman for both the program and ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  ... Director and one of the founding commercial leaders responsible for the commercialization of ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. ... Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from the ... the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy Ph.D. ...
(Date:4/26/2016)... (PRWEB) , ... April 27, 2016 , ... ... of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual ... and international electrical, mechanical and electromechanical patent applications. He has an electrical engineering ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):